Recai Türkoğlu
YOU?
Author Swipe
View article: Baseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis
Baseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis Open
Baseline NFL and BDNF levels effectively predict the development of AMS emerging early in the course of MS. Combined use of these molecular markers with MRI results may enable early diagnosis and appropriate therapeutic intervention of AMS.
View article: Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability Open
Importance Understanding the association between pregnancy and clinical outcomes in women with moderate to severe multiple sclerosis (MS) disability is crucial for guiding family planning and management strategies. Objective To assess peri…
View article: Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024) Open
Background: Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associa…
View article: EFFICACY OF INTRAVENOUS METHYLPREDNISOLONE VS INTRAVENOUS METHYLPREDNISOLONE+PLASMAPHERESİS IN NMOSD ATTACKS
EFFICACY OF INTRAVENOUS METHYLPREDNISOLONE VS INTRAVENOUS METHYLPREDNISOLONE+PLASMAPHERESİS IN NMOSD ATTACKS Open
Our results suggest that the addition of PLEX to IVMP treatment might be suitable especially for severe NMOSD attacks.
View article: Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies Open
This study provides Class III evidence that for women with relapsing-remitting MS or clinically isolated syndrome who become pregnant, ocrelizumab, rituximab, and natalizumab (continued ≥28 weeks of gestation and restarted ≤1 month postpar…
View article: Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study Open
Background Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative…
View article: Seronegative NMOSD patients display distinctive peripheral blood T-cell subset frequencies
Seronegative NMOSD patients display distinctive peripheral blood T-cell subset frequencies Open
Journal Article Accepted manuscript Letter to the Editor: Seronegative NMOSD patients display distinctive peripheral blood T cell subset frequencies Get access Elif Sanli, Elif Sanli Department of Neuroscience, Aziz Sancar Institute of Exp…
View article: Effect of Telerehabilitation on Verbal and Visual Memory in Multiple Sclerosis Patients: A 12-month Follow-up Study
Effect of Telerehabilitation on Verbal and Visual Memory in Multiple Sclerosis Patients: A 12-month Follow-up Study Open
Objective: Conditions such as chronic fatigue or physical disability, particularly regular work, limit the treatment options that require continuous participation in multiple sclerosis (MS) patients.The pandemic period highlighted the impo…
View article: Effects of Neurocognitive Rehabilitation on the Levels of Neurotransmitters and Memory Proteins in Patients with Multiple Sclerosis
Effects of Neurocognitive Rehabilitation on the Levels of Neurotransmitters and Memory Proteins in Patients with Multiple Sclerosis Open
Objective: This study aimed to investigate the role of neurotrophic factors and neurotransmitters in the neurocognitive impairments observed in Multiple Sclerosis (MS) patients, explore potential biomarkers, and evaluate the impact of comp…
View article: The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable Open
Geographical variations in the incidence and prevalence of multiple sclerosis have been reported globally. Latitude as a surrogate for exposure to ultraviolet radiation but also other lifestyle and environmental factors are regarded as dri…
View article: Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis Open
Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS…
View article: Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis Open
Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-…
View article: Disability accrual in primary and secondary progressive multiple sclerosis
Disability accrual in primary and secondary progressive multiple sclerosis Open
Background Some studies comparing primary and secondary progressive multiple sclerosis (PPMS, SPMS) report similar ages at onset of the progressive phase and similar rates of subsequent disability accrual. Others report later onset and/or …
View article: Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis Open
Background: The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. Objective: To determine whether early non-disabling relapses predict disability accumulation in RRMS…
View article: Comparative effectiveness in multiple sclerosis: A methodological comparison
Comparative effectiveness in multiple sclerosis: A methodological comparison Open
Background: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trials and guide clinical decisions. Observational studies are, however, susceptible to confounding and bias. Amon…
View article: Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis
Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis Open
Background and Objectives: antibodies to CD20 efficiently reduce new relapses in multiple sclerosis (MS), and ocrelizumab has been shown to be effective also in primary progressive MS. Although anti-CD20 treatments efficiently deplete B ce…
View article: Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis Open
Background and purpose This study assessed the effect of patient characteristics on the response to disease‐modifying therapy (DMT) in multiple sclerosis (MS). Methods We extracted data from 61,810 patients from 135 centers across 35 count…
View article: The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis Open
Natalizumab and ocrelizumab exhibited similar effects on relapse control, and both were associated with better relapse control than fingolimod. The effects of the three therapies on disability outcomes were similar.
View article: Correction: Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment
Correction: Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment Open
[This corrects the article on p. 23 in vol. 60, PMID: 36911568.].
View article: Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE) Open
The present study revealed superior effectiveness of vertical switch over lateral switch regarding the improvement in relapse outcomes. Patients in the FNG cohort experienced sustainably fewer relapses during the follow-up period after the…
View article: Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis Open
This study provides Class III that disease reactivation occurs within months of discontinuation of MS disease-modifying therapies. The risk of disease activity is reduced by commencement of a subsequent therapy.
View article: The Multiple Sclerosis Functional Composite (MSFC) for Determining Disease Progression: A Methodological Study
The Multiple Sclerosis Functional Composite (MSFC) for Determining Disease Progression: A Methodological Study Open
Objective: The methods used in monitoring the progression of multiple sclerosis (MS) and evaluating the effectiveness of disease-modifying treatments are insufficient.Data obtained from the expanded disability status scale (EDSS), annual r…
View article: Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder Open
Fingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD.